MetaCap

Pulmatrix (PULM) vs Soligenix (SNGX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Soligenix is the larger company by market cap ($5.1 million vs $4.6 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

PULM-14.77%SNGX-37.74%
+8%-16%-40%
Oct 7, 20261 yearNov 20, 2026
PULM-13.01%SNGX-39.47%
+3%-19%-42%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

PULM versus SNGX key metrics
MetricPULMSNGX
Share price$1.27$0.2201
Market cap$4.64M$5.14M
1-day change-10.56%-8.29%
EPS (TTM)$-1.20$-0.21
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-5.16M$-11.08M
52-week high$4.94$1.70
52-week low$1.06$0.21
Distance from 52-week high-74.29%-87.05%
Analyst consensus—none
Avg. price target upside—+526.99%
Average volume35.45K198.15K
Shares outstanding3.65M23.37M
Employees213
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Pulmatrix

PULM stock →

Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.

Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees

About Soligenix

SNGX stock →

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions.

Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees

PULM vs SNGX FAQ

Which is bigger, Pulmatrix or Soligenix?

Soligenix (SNGX) is larger, with a market capitalization of $5.14M compared with $4.64M for Pulmatrix (PULM).

Are Pulmatrix and Soligenix in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons